Abstract
Introduction
Familial Mediterranean fever (FMF) has been considered to be an autosomal recessive trait which is characterized by self-limiting recurrent fever and serositis (OMIM #249100), [1] and categorized to an autoinflammatory disease. [2] MEFV, which was identified as the responsible gene for FMF, encodes cytosolic protein pyrin (also known as marenostrin) which regulates the activity of NLRP3 inflammasome. [3] Two hundred and ninety six sequence variants in MEFV gene have been registered to "Infevers" database (http://fmf.igh.cnrs.fr/ISSAID/ infevers/) as of September 1st, 2014, including hot spots for pathogenic amino acid substitutions in the C-terminus region of the protein. Recently, dominant form (OMIM #134610) of the disease was reported, [4] and overlapping and continuum to other autoinflammatory diseases were proposed. [5] We performed a nation-wide surveillance of FMF in Japan and found that only M694I is commonly identified among hot spot mutations in the exon 10, homozygotes of which comprise as many as 10% of Japanese FMF. [6] We also noticed that more than one third of the patients did not carry two copies of pathological mutations in their MEFV gene. [6] It is possible that the indistinct genotype-phenotype correlation observed in Japanese FMF is owing to the effect of modifier genes. Genes in the HLA region are candidates for the modifier genes because they are involved in various inflammatory diseases such as ankylosing spondylitis, [7] rheumatoid arthritis, [8] and Behçet's disease. [9] In the present study, we examined the effect of carrier status of HLA-B and-DRB1 alleles on FMF by the comparison of the frequencies between patients and non-disease control individuals by employing the probands of FMF pedigree and sporadic FMF cases who were captured by our previous national surveillance study. [6] HLA effects on clinical forms of FMF, subsets of FMF with certain MEFV genotypes and poor responders to colchicine treatment were also evaluated.
Methods

Study population
Blood samples were donated by the probands of FMF pedigree or sporadic cases of FMF, who satisfied the modified Tel-Hashomer criteria for FMF with either "typical" or "incomplete" attacks, [10] after the acquisition of written informed consent from each patient. Information about clinical feature was reported by health care providers participated to national surveillance study in Japan as reported previously; [6] in brief, epidemiological data (including gender, consanguinity of parents, familial history and age of onset of inflammation signs) and major clinical data (including fever, thoracic, abdominal, articular, cutaneous signs, duration and frequency of episodes, presence of amyloidosis, and response to colchicine) were provided by a standard form. Differential diagnosis between typical and incomplete attacks was made according to the following criteria: a typical FMF attack is defined as 3 or more episodes of generalized peritonitis, or monoarthritis of the hip, knee or ankle lasting 12 hours to 3 days with a fever of 38°C or more, while an incomplete attack is defined as a fever less than 38°C of ill-defined duration (from 6 hours to 1 week), no sign of peritonitis or localized abdominal sign during abdominal attack and atypical distribution of arthritis. [6] Genotype of MEFV was determined during a diagnostic procedure; [6] E84K, L110P, E148Q, R202Q, E225K, G304R, R354Q, P369S, R408Q, R410H, S503C, M694I and P751L were identified. All the study procedures were approved by institutional review boards of National Hospital Organization Nagasaki Medical Center and Nagasaki University.
HLA-B and -DRB1 genotyping DNA was extracted from the blood sample and subjected to HLA-B and-DRB1 genotype determination by WAKFlow HLA typing kit (Wakunaga Pharmaceutical, Osaka, Japan) based on the reverse sequence-specific oligonucleotide probes method coupled with xMAP technology designed for use with the Luminex system (Luminex Japan, Tokyo, Japan).
Statistics
The risk/protective effects of carrier status of HLA alleles were evaluated by odds ratio (OR) obtained by the comparison of frequencies between patients and controls. HLA genotype data of 299 healthy volunteers, who were staff of National Hospitals, were used as controls in the present study. Independency or interaction between HLA factors was assessed by subgroup analysis after the stratification by carrier status of HLA alleles of interest. Further, the HLA effect on the responsiveness to colchicine treatment was evaluated by the comparison of HLA carrier status between poor responders and responders. All the statistical analyses were performed using STATA12 (StataCorp, College Station, TX, USA).
Results
Clinical feature of patients with FMF
Two hundred fifty eight mutually unrelated patients with FMF were enrolled in the present study. Among them, 149 met the criteria for "typical" FMF (FMF with typical attacks) and the other 109 were classified as "incomplete" FMF patients (patients with incomplete FMF attacks). MEFV M694I was carried by 85 FMF patients (32.9%) and 159 patients (61.6%) possessed two copies of MEFV sequences with detectable pathological mutations ( Table 1 ). In accordance with our previous report, [6] HLA effects on the clinical forms of FMF and MEFV genotype Next, the HLA effects were examined for two clinical forms of FMF, typical and incomplete FMF, as well as patients with certain MEFV genotypes ( Table 2 ). The precipitating effect of B Ã 39:01 was observed in incomplete FMF and patients without high-penetrance MEFV allele M694I with higher OR and smaller p value than the comparison between FMF and controls (OR = 4.30 and 3.83, p = 0.00028 and 0.00037, respectively), but not in typical FMF or patients carrying M694I. In contrast, the protective effect of DRB1 Ã 15:02 was evident in both typical and incomplete FMF (OR = 0.55 and 0.32, p = 0.025 and 0.0010) and in both carriers and noncarriers of M694I (OR = 0.47 and 0.42, p = 0.028 and 0.0013), while the effect was slightly stronger in incomplete FMF and patients without M694I. The major HLA effects were augmented in the patients without canonical MEFV variant allele M694I, in accordance with the notion that the lower penetrance in the subset of the disease is owing to the larger contribution of modifiers in the pathogenesis. 
Response to colchicine treatment
Although the good response to the treatment with oral colchicine administration is one of diagnostic criteria for FMF, [10] a relatively small but not negligible part of the patients are resistant to colchicine-treatment and require alternative anti-inflammatory treatment. Among 170 patients whose clinical data for the response to colchicine were available, 14 patients (8.2%) were clinically classified as non-responders to colchicine-treatment. When the HLA alleles significantly associated with FMF, clinical forms of FMF or subgroups of the patients with characteristic MEFV genotypes identified above were analyzed ( 
Discussion
Similarity to other inflammatory diseases with respect to HLA-disease association and differential effects of HLA classes
As an attempt to identify a modifier gene of FMF, we analyze polymorphisms in the HLA-B and-DRB1 loci because of their possible roles in the determination of antigen specificity in immune response as well as known association with various health conditions including 
Common genetic predisposition to FMF and other inflammatory diseases
It has been reported that the patients with FMF are predisposed to other inflammatory diseases such as ankylosing spondylitis and Behçet disease. [23, 24] MEFV mutations play a role to increase the risk of these diseases even among the patients without the complication of FMF. [25] [26] [27] [28] Although it still remains unclear how the symptoms of periodical fevers of FMF are triggered, the MEFV product interacts with cellular components of inflammasome whose activity is augmented by the pathogenic mutations. [29] Therefore, it is reasonable to consider that FMF-associated MEFV mutations enhance the cellular responses in the inflammatory diseases which are also associated with certain HLA polymorphisms. Uncovering of the common underlying mechanism in the pathogenesis of these inflammatory diseases in the context of HLA-MEFV interaction would be helpful to find an effective target of novel therapeutic or preventive measures.
Predictors of colchicine response
Colchicine is the first choice of the medical treatment of FMF. The response to colchicine is one of remarkable characteristics of FMF and has been a very effective criterion for the differential diagnosis FMF from other inflammatory diseases. In the present study, 14 of 170 patients (8.2%) whose response to colchicine treatment was available were reported as poor responders by care-providing physicians. It has been widely recognized that 5-15% of the patients with FMF do not respond to colchicine. [30] We did not examine ABCB1 polymorphisms which are associated with colchicine non-responders, [31] in the present study, but six HLA-B Ã 35:01-carriers were identified among poor responders (42.9%) giving a significant increase in the carrier frequency in comparison to colchicine responders. The positive predictive value of HLA-B Ã 35:01-carriage remained as much as 0.24, but it was a moderately useful predictor of prognosis as assessed by positive likelihood ratio of 4.35. [32] Despite nation-wide collection of FMF in Japan, the evaluation of predictors of colchicine response was made with relatively small number of poor responders only whose clinical documents were available. Therefore the result of the present study should be confirmed by more colchicine poor responders. None the less for this limitation, combination with other prognostic markers such as ABCB1 SNPs may improve the accuracy of prediction to meet practical demands.
Conclusions
The differential effects of HLA class I and class II alleles on FMF were identified for Japanese population. Modifier genes including HLA explain low penetrance of non-canonical mutations at least in part. Further, HLA-B Ã 35:01 can be a useful predictive marker for the failure of colchicine treatment.
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